Repro Med Systems
KRMDRepro Med Systems in brief
Repro Med Systems is a listed company in the Medical Instruments industry, based in Mahwah, New Jersey, USA. Its market value was $140 M on 29 October 2026, which makes it the 17,538th largest listed company in the world and the 3,340th largest in the USA on this site. In the year to December 2025 it had sales of $41 M and a net loss of $3 M. Linda M. Tharby is its chief executive. By market, the largest shares of its 2025 sales came from USA (74%). Its shares trade under the symbol KRMD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Repro Med Systems timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- ✎Renamed KORU Medical Systems, Inc.Formerly Repro Med Systems Inc.
- 2025
- 💰Record revenue of $41 millionFY2025, the highest of the 8 years on record.
Events of Repro Med Systems from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,053 (Jan 2020) · #3,050 (Jan 2021) · #4,185 (Jan 2022) · #3,916 (Dec 2022) · #4,026 (Jul 2023) · #3,682 (Jan 2024) · #1,683 (Mar 2026) · #3,219 (Aug 2026) · #3,317 (Sep 2026) · #3,344 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 3.0×
- Price / book
- 8.2×
- Free cash flow yield
- -0.3%
- Net margin (TTM)
- -1.8%
- Operating margin
- -7.2%
- Return on equity
- -4.8%
- Liabilities / assets
- 39.5%
- Net debt
- $-2M
- Revenue growth
- +22.2%
- R&D / revenue
- 10.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $41M | +22.2% | $-3M | $-3M | -6.4% |
| Dec 2024 | $34M | +18.0% | $-6M | $-6M | -18.0% |
| Dec 2023 | $29M | +2.2% | $-10M | $-14M | -48.2% |
| Dec 2022 | $28M | +18.8% | $-11M | $-9M | -31.0% |
| Dec 2021 | $23M | -2.9% | $-7M | $-5M | -19.4% |
| Dec 2020 | $24M | +4.4% | $-1M | $-1M | -5.0% |
| Dec 2019 | $23M | +33.5% | $1M | $1M | 2.4% |
| Dec 2018 | $17M | — | $1M | $1M | 5.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $0M | $1M | $-0M | $-0.06 | — |
| Dec 2024 | $-0M | $1M | $-2M | $-0.13 | — |
| Dec 2023 | $-5M | $1M | $-6M | $-0.30 | — |
| Dec 2022 | $-5M | $3M | $-8M | $-0.19 | — |
| Dec 2021 | $-4M | $0M | $-5M | $-0.10 | — |
| Dec 2020 | $-1M | $1M | $-2M | $-0.03 | — |
| Dec 2019 | $0M | $0M | $0M | $0.01 | — |
| Dec 2018 | $1M | $0M | $1M | $0.02 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $12M (+11.2% on a year earlier), net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 14, 20268-KCurrent reportBylaws amended
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 30, 20268-KCurrent reportMaterial agreement
- May 21, 20268-KCurrent reportShareholder vote
- May 6, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations
- Apr 9, 2026DEF 14AProxy statement
- Apr 3, 20268-KCurrent reportMaterial agreement · New financial obligation
- Mar 16, 20268-KCurrent reportDirectors or officers changed
Official filings of Repro Med Systems with the US Securities and Exchange Commission.
Annual results
- Revenue
- $41 M
- Operating income
- $-3 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $28 M
- Total liabilities
- $11 M
- Total equity
- $17 M
As of December-2025
Top 85 institutional investors in Repro Med Systems#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Topline Capital Management, LLC | 4,333,201 | +959,359 (+28.44%) | 9.99% | $13 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 2,781,721 | +153,369 (+5.84%) | 6.41% | $8 M | Nov 13, 2026 |
| 3 | First Light Asset Management, LLC | 2,745,372 | -642,530 (-18.97%) | 6.33% | $8 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 1,690,732 | -127,389 (-7.01%) | 3.90% | $5 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 1,040,708 | -87,388 (-7.75%) | 2.40% | $3 M | Nov 6, 2026 |
| 6 | Simcoe Capital LLC | 713,392 | -114,001 (-13.78%) | 1.64% | $2 M | Nov 5, 2026 |
| 7 | Archon Capital Management LLC | 648,695 | +5,772 (+0.90%) | 1.50% | $2 M | Nov 16, 2026 |
| 8 | State Street Corp | 634,332 | -12,240 (-1.89%) | 1.46% | $2 M | Nov 12, 2026 |
| 9 | Meros Investment Management, LP | 508,779 | -250,885 (-33.03%) | 1.17% | $1 M | Nov 17, 2026 |
| 10 | HRT Financial LP | 375,703 | +22,531 (+6.38%) | 0.87% | $1 M | Nov 13, 2026 |
| 11 | Northern Trust Corp | 343,110 | -4,063 (-1.17%) | 0.79% | $1 M | Nov 16, 2026 |
| 12 | Vanguard Portfolio Management LLC | 305,435 | -4,398 (-1.42%) | 0.70% | $1 M | Nov 13, 2026 |
| 13 | White Pine Capital LLC | 286,644 | +2,541 (+0.89%) | 0.66% | $1 M | Nov 9, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 285,044 | -41,053 (-12.59%) | 0.66% | $1 M | Nov 13, 2026 |
| 15 | Marshall Wace, LLP | 244,902 | +223,406 (+1039.29%) | 0.56% | $1 M | Nov 13, 2026 |
| 16 | Renaissance Technologies LLC | 235,800 | +70,900 (+43.00%) | 0.54% | $1 M | Nov 12, 2026 |
| 17 | Arrowstreet Capital, Limited Partnership | 213,782 | +160,910 (+304.34%) | 0.49% | $1 M | Nov 13, 2026 |
| 18 | Morgan Stanley | 196,599 | -126,360 (-39.13%) | 0.45% | $1 M | Nov 13, 2026 |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 188,397 | +35,453 (+23.18%) | 0.43% | $1 M | Nov 10, 2026 |
| 20 | Albion Financial Group /ut | 186,374 | 0 (0.00%) | 0.43% | $1 M | Oct 21, 2026 |
| 21 | Squarepoint Ops LLC | 173,132 | +48,377 (+38.78%) | 0.40% | $1 M | Nov 9, 2026 |
| 22 | Citadel Advisors LLC | 172,989 | +144,469 (+506.55%) | 0.40% | $1 M | Nov 16, 2026 |
| 23 | Qube Research & Technologies Ltd | 137,527 | -62,412 (-31.22%) | 0.32% | $0 M | Nov 13, 2026 |
| 24 | HighMark Wealth Management LLC | 120,935 | 0 (0.00%) | 0.28% | $0 M | Nov 17, 2026 |
| 25 | Goldman Sachs Group Inc | 120,375 | +19,900 (+19.81%) | 0.28% | $0 M | Nov 16, 2026 |
Show all 85: investors 26 to 85
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Charles Schwab Investment Management Inc | 115,173 | -11,537 (-9.11%) | 0.27% | $0 M | Nov 16, 2026 |
| 27 | Strs Ohio | 104,100 | +29,900 (+40.30%) | 0.24% | $0 M | Oct 30, 2026 |
| 28 | PNC Financial Services Group, Inc. | 97,040 | +40 (+0.04%) | 0.22% | $0 M | Nov 6, 2026 |
| 29 | Gsa Capital Partners LLP | 90,046 | +60,420 (+203.94%) | 0.21% | $0 M | Nov 16, 2026 |
| 30 | Bank of New York Mellon Corp | 89,441 | +1,736 (+1.98%) | 0.21% | $0 M | Nov 5, 2026 |
| 31 | Lakewood Asset Management LLC | 73,945 | 0 (0.00%) | 0.17% | $0 M | Oct 26, 2026 |
| 32 | Nuveen, LLC | 56,564 | +1,234 (+2.23%) | 0.13% | $0 M | Nov 10, 2026 |
| 33 | HighTower Advisors, LLC | 51,400 | +25 (+0.05%) | 0.12% | $0 M | Nov 10, 2026 |
| 34 | Bank Of America Corp /de/ | 48,842 | +19,238 (+64.98%) | 0.11% | $0 M | Nov 16, 2026 |
| 35 | Rhumbline Advisers | 44,899 | +15,768 (+54.13%) | 0.10% | $0 M | Nov 10, 2026 |
| 36 | Acadian Asset Management LLC | 43,305 | New | 0.10% | $0 M | Nov 9, 2026 |
| 37 | Deutsche Bank AG\ | 38,160 | -5,445 (-12.49%) | 0.09% | $0 M | Nov 6, 2026 |
| 38 | Price T Rowe Associates Inc /MD/ | 36,991 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 39 | Bridgeway Capital Management, LLC | 36,805 | -15,000 (-28.95%) | 0.08% | $0 M | Nov 16, 2026 |
| 40 | Invesco Ltd. | 36,689 | +1,353 (+3.83%) | 0.08% | $0 M | Nov 12, 2026 |
| 41 | Osaic Holdings, Inc. | 32,570 | +8,300 (+34.20%) | 0.08% | $0 M | Nov 12, 2026 |
| 42 | Quadrature Capital Ltd | 30,620 | New | 0.07% | $0 M | Nov 13, 2026 |
| 43 | Corient Private Wealth LP | 29,885 | New | 0.07% | $0 M | Nov 16, 2026 |
| 44 | Algert Global LLC | 28,107 | +5,370 (+23.62%) | 0.06% | $0 M | Nov 17, 2026 |
| 45 | Two Sigma Investments, LP | 25,594 | +10,983 (+75.17%) | 0.06% | $0 M | Nov 16, 2026 |
| 46 | Susquehanna International Group, LLP | 25,535 | New | 0.06% | $0 M | Nov 16, 2026 |
| 47 | Dimensional Fund Advisors LP | 24,380 | New | 0.06% | $0 M | Nov 4, 2026 |
| 48 | Russell Investments Group, Ltd. | 24,231 | -245,355 (-91.01%) | 0.06% | $0 M | Nov 6, 2026 |
| 49 | Centiva Capital, LP | 24,215 | +9,003 (+59.18%) | 0.06% | $0 M | Nov 13, 2026 |
| 50 | Wealthspire Advisors, LLC | 23,425 | +2,000 (+9.33%) | 0.05% | $0 M | Nov 13, 2026 |
| 51 | Occudo Quantitative Strategies LP | 22,455 | -1,419 (-5.94%) | 0.05% | $0 M | Nov 16, 2026 |
| 52 | Jpmorgan Chase & Co | 22,202 | +2,440 (+12.35%) | 0.05% | $0 M | Nov 12, 2026 |
| 53 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 21,871 | +1,102 (+5.31%) | 0.05% | $0 M | Nov 16, 2026 |
| 54 | Walleye Capital LLC | 21,364 | New | 0.05% | $0 M | Nov 13, 2026 |
| 55 | Vanguard Global Advisers, LLC | 20,170 | +224 (+1.12%) | 0.05% | $0 M | Nov 13, 2026 |
| 56 | Captrust Financial Advisors | 20,072 | New | 0.05% | $0 M | Nov 12, 2026 |
| 57 | Barclays PLC | 16,754 | +10,191 (+155.28%) | 0.04% | $0 M | Nov 6, 2026 |
| 58 | Mesirow Financial Investment Management, Inc. | 16,459 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 59 | Bard Associates Inc | 16,004 | +1,414 (+9.69%) | 0.04% | $0 M | Nov 13, 2026 |
| 60 | Jump Financial, LLC | 14,015 | New | 0.03% | $0 M | Nov 13, 2026 |
| 61 | Millennium Management LLC | 13,436 | -2,920 (-17.85%) | 0.03% | $0 M | Nov 16, 2026 |
| 62 | Wells Fargo & Company/mn | 13,254 | -27,877 (-67.78%) | 0.03% | $0 M | Nov 16, 2026 |
| 63 | New York State Common Retirement Fund | 13,163 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 64 | Engineers Gate Manager LP | 13,091 | New | 0.03% | $0 M | Nov 16, 2026 |
| 65 | BNP Paribas Financial Markets | 11,546 | +3,724 (+47.61%) | 0.03% | $0 M | Nov 12, 2026 |
| 66 | Baird Financial Group, Inc. | 11,000 | New | 0.03% | $0 M | Nov 13, 2026 |
| 67 | UBS Group AG | 10,769 | +4,856 (+82.12%) | 0.02% | $0 M | Nov 10, 2026 |
| 68 | Royal Bank Of Canada | 10,097 | +5,073 (+100.98%) | 0.02% | $0 M | Nov 16, 2026 |
| 69 | Tower Research Capital LLC (TRC) | 9,431 | +5,861 (+164.17%) | 0.02% | $0 M | Nov 16, 2026 |
| 70 | Police & Firemen's Retirement System of New Jersey | 8,255 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 71 | FMR LLC | 7,939 | +2,259 (+39.77%) | 0.02% | $0 M | Nov 10, 2026 |
| 72 | Citigroup Inc | 5,781 | -15,357 (-72.65%) | 0.01% | $0 M | Nov 4, 2026 |
| 73 | Ameritas Investment Partners, Inc. | 4,336 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 74 | Legal & General Group Plc | 3,868 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 75 | Steward Partners Investment Advisory, LLC | 1,898 | +1,078 (+131.46%) | 0.00% | $0 M | Nov 13, 2026 |
| 76 | BFC Planning, Inc. | 1,500 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 77 | Sterling Capital Management LLC | 1,479 | +1,321 (+836.08%) | 0.00% | $0 M | Oct 22, 2026 |
| 78 | California State Teachers Retirement System | 606 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 79 | TD Private Client Wealth LLC | 286 | New | 0.00% | $0 M | Oct 28, 2026 |
| 80 | Allworth Financial LP | 56 | +36 (+180.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 81 | SJS Investment Consulting Inc. | 30 | +29 (+2900.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 82 | Nisa Investment Advisors, LLC | 25 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 83 | Caitong International Asset Management Co., Ltd | 17 | +14 (+466.67%) | 0.00% | $0 M | Oct 29, 2026 |
| 84 | Arax Advisory Partners | 2 | -17 (-89.47%) | 0.00% | $0 M | Nov 12, 2026 |
| 85 | Essential Partners LLC | 1 | -2 (-66.67%) | 0.00% | $0 M | Oct 14, 2026 |
Mutual funds holding Repro Med Systems#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.25 M | $5 M | 2.9% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.14 M | $5 M | 2.6% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 520,942 | $2 M | 1.2% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 488,221 | $2 M | 1.1% | <0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 423,433 | $2 M | 0.98% | 0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 241,876 | $1 M | 0.56% | <0.01% | −0.7% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 222,972 | $1 M | 0.51% | <0.01% | +4.5% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 151,633 | $1 M | 0.35% | 0.04% | +39% | Jun 30, 2026 |
| 🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust | 129,708 | $1 M | 0.30% | 0.07% | −27% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 113,897 | $0 M | 0.26% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 83,808 | $0 M | 0.19% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 73,581 | $0 M | 0.17% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 70,974 | $0 M | 0.16% | <0.01% | +6.2% | May 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 65,630 | $0 M | 0.15% | 0.03% | +1.3% | May 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 56,139 | $0 M | 0.13% | 0.20% | — | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 55,330 | $0 M | 0.13% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 42,991 | $0 M | 0.10% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 42,506 | $0 M | 0.10% | 0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 39,645 | $0 M | 0.09% | <0.01% | −0.9% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 30,800 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 31,356 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 24,670 | $0 M | 0.06% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 24,313 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 21,744 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 21,542 | $0 M | 0.05% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 18,124 | $0 M | 0.04% | <0.01% | −26% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 17,200 | $0 M | 0.04% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 16,177 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 15,406 | $0 M | 0.04% | <0.01% | +8.3% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 12,813 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 10,668 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,201 | $0 M | 0.02% | 0.02% | +35% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 9,139 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,439 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 8,148 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 7,907 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC | 7,823 | $0 M | 0.02% | 0.02% | −2.9% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 7,332 | $0 M | 0.02% | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,134 | $0 M | 0.02% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,797 | $0 M | 0.02% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,492 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,165 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,977 | $0 M | 0.01% | <0.01% | +0.4% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,828 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,336 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 4,277 | $0 M | <0.01% | 0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 4,145 | $0 M | <0.01% | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,100 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,650 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,518 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,448 | $0 M | <0.01% | <0.01% | +6.3% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,237 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,100 | $0 M | <0.01% | <0.01% | +72% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 3,100 | $0 M | <0.01% | <0.01% | +72% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,033 | $0 M | <0.01% | <0.01% | +8.5% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,590 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,608 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,413 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,398 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,026 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 244 | $0 M | <0.01% | <0.01% | +16% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 61 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Repro Med Systems#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Eric SchillerChief Technology Officer | Buy | +8,546 | $3.630 | $31 K | 13,546 | Form 4 |
| filed | Robert CascellaDirector | Grant or award | +5,119 | $2.930 | $15 K | 103,274 | Form 4 |
| filed | R. John FletcherDirector | Grant or award | +7,679 | $2.930 | $22 K | 239,836 | Form 4 |
| filed | Donna FrenchDirector | Grant or award | +5,119 | $2.930 | $15 K | 103,633 | Form 4 |
| filed | Shahriar MatinDirector | Grant or award | +5,119 | $2.930 | $15 K | 106,263 | Form 4 |
| filed | Edward WholihanDirector | Grant or award | +5,119 | $2.930 | $15 K | 56,431 | Form 4 |
| filed | Joseph M. Manko Jr.Director, 10% owner | Grant or awardindirect | +5,119 | — | — | 5.07 M | Form 4 |
| filed | Adam R. KalbermattenChief Commercial Officer | Buy | +32,000 | $3.160 | $101 K | 394,017 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Repro Med Systems#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2019 | Q4 2020 | $0M |
| Q3 2019 | Q3 2020 | $0M |
| Q2 2019 | Q2 2020 | $0M |
| Q1 2019 | Q1 2020 | $0M |
Fails to deliver
- : 5,015 shares at $3.22
- : 1,024 shares at $3.02
- : 10,595 shares at $3.00
- : 94,311 shares at $3.22
- : 96,411 shares at $3.20
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Repro Med Systems scorecard#
Passes 8 of the 20 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median8.2×Price to book 8.2× against Medical Instruments's median of 3.9×.
- ✗Price to sales below its peers' median3.0×Price to sales 3.0× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%-0.3%Free cash flow is -0.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year22.2%Revenue up 22.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years13.8%13.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median13.8%13.8% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-0.06 vs -0.13Diluted EPS -0.06 in fiscal 2025 against -0.13 the year before (report's currency).
- ✗Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$1 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-7.2%-7.2% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%-15.6%-15.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-7.2%-7.2% in fiscal 2025 against -38.6% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.44 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone7.54Z-score 7.54 (safe zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.8%Diluted shares up 0.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Repro Med Systems's statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -7.2% | 7.2% | |
| Net margin | -6.4% | 3.8% | |
| Return on equity | -15.6% | 3.5% | |
| Revenue growth, 3 years a year | 13.8% | 5.0% | |
| Revenue growth | 22.2% | 8.9% | |
| Free cash flow margin | -1.1% | 6.3% |
4of 8on the Piotroski tests of financial strength
- Net loss of $3 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$0 million.
- Revenue has grown 4 years in a row.
Repro Med Systems: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2016to Feb 28, 2017 | FY 2015to Feb 29, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 41,127+22.2%100% | 33,646+18.0%100% | 28,518+2.2%100% | 27,896+18.8%100% | 23,490−2.8%100% | 24,176+4.4%100% | 23,163+33.5%100% | 17,354—100% | 12,294+0.4%100% | 12,247—100% | |
| Cost of revenue | 15,523+26.1%37.7% | 12,315+4.3%36.6% | 11,809−5.7%41.4% | 12,527+28.9%44.9% | 9,721+5.2%41.4% | 9,240+11.2%38.2% | 8,309+27.0%35.9% | 6,543—37.7% | 4,724+1.7%38.4% | 4,644—37.9% | |
| Gross profit | 25,604+20.0%62.3% | 21,332+27.7%63.4% | 16,708+8.7%58.6% | 15,369+11.6%55.1% | 13,770−7.8%58.6% | 14,936+0.6%61.8% | 14,854+37.4%64.1% | 10,810—62.3% | 7,570−0.4%61.6% | 7,603—62.1% | |
| Research and development | 4,387−16.6%10.7% | 5,258−8.4%15.6% | 5,742+15.9%20.1% | 4,956+100%17.8% | 2,474+90.8%10.5% | 1,297+75.1%5.4% | 740+207%3.2% | 241—1.4% | 237+14.6%1.9% | 207—1.7% | |
| Selling, general and administrative | 23,379+8.1%56.8% | 21,632+6.2%64.3% | 20,366−1.2%71.4% | 20,607+15.4%73.9% | 17,862+48.5%76.0% | 12,028+23.1%49.8% | 9,772+19.2%42.2% | 8,197r9,096—47.2% | 7,768+30.7%63.2% | 5,943—48.5% | |
| Operating expenses | 28,577+2.9%69.5% | 27,778+3.0%82.6% | 26,978+3.2%94.6% | 26,150+25.7%93.7% | 20,799+28.5%88.5% | 16,191+13.5%67.0% | 14,268+47.9%61.6% | 9,646—55.6% | 8,306+29.3%67.6% | 6,422—52.4% | |
| Operating income | −2,972—−7.2% | −6,446—−19.2% | −10,270—−36.0% | −10,781—−38.6% | −7,030—−29.9% | −1,255−314%−5.2% | 586−49.7%2.5% | 1,165—6.7% | −736−162%−6.0% | 1,181—9.6% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 1.9−44.7%0.0% | 3.4—0.0% | |
| Provision for credit losses | — | — | — | — | — | −8.2—−0.0% | −4.9—−0.0% | −40—−0.2% | — | — | |
| Other non-operating income (expense) | 356−6.8%0.9% | 382−22.9%1.1% | 496+370%1.7% | 106−84.1%0.4% | 665+999%2.8% | 61−45.3%0.3% | 111r81+294%0.5% | 28—0.2% | 2.9—0.0% | −9.2—−0.1% | |
| Income before tax | −2,616—−6.4% | −6,064—−18.0% | −9,774—−34.3% | −10,675—−38.3% | −6,364r6,364−633%−27.1% | 1,194r−1,194+71.5%4.9% | 696−40.8%3.0% | 1,177—6.8% | −777−168%−6.3% | 1,143—9.3% | |
| Income tax | 22+657%0.1% | 2.9−99.9%0.0% | 3,967—13.9% | −2,014—−7.2% | −1,802r1,802—−7.7% | −18r18−113%−0.1% | 132−50.4%0.6% | 266—1.5% | −242−167%−2.0% | 360—2.9% | |
| Net income attributable to shareholders | −2,638—−6.4% | −6,067—−18.0% | −13,741—−48.2% | −8,661—−31.0% | −4,563—−19.4% | −1,212−315%−5.0% | 564−38.0%2.4% | 911—5.2% | −535−168%−4.4% | 783—6.4% | |
| Earnings per share, basic | -0.06—— | -0.13—— | -0.30—— | -0.19—— | -0.10—— | -0.03−400%— | 0.01−50.0%— | 0.02—— | -0.01−150%— | 0.02—— | |
| Earnings per share, diluted | -0.06—— | -0.13—— | -0.30—— | -0.19—— | -0.10—— | -0.03−400%— | 0.01−50.0%— | 0.02—— | -0.01−150%— | 0.02—— | |
| Shares, weighted average (basic) | 46+0.8%— | 46+0.4%— | 46+1.3%— | 45+1.4%— | 44+5.9%— | 42+8.1%— | 39+1.7%— | 38—— | 38−0.4%— | 38—— | |
| Shares, weighted average (diluted) | 46+0.8%— | 46+0.4%— | 46+1.3%— | 45+1.4%— | 44+5.9%— | 42+7.3%— | 39+0.4%— | 39—— | 38−0.3%— | 38—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8,872−7.4%31.5% | 9,581−16.6%35.2% | 11,482−34.0%40.3% | 17,408−31.3%41.1% | 25,335−7.3%61.4% | 27,315+365%68.4% | 5,871+57.0%42.3% | 3,739—35.5% | 3,313−21.1%40.6% | 4,202r4,202—50.1% | |
| Receivables | 6,210+8.6%22.0% | 5,721+41.4%21.0% | 4,045+13.7%14.2% | 3,559−0.9%8.4% | 3,593+39.6%8.7% | 2,573−20.5%6.4% | 3,235+127%23.3% | 1,426—13.5% | 1,502+11.2%18.4% | 1,350—16.1% | |
| Inventory | 3,678+31.2%13.0% | 2,804−19.5%10.3% | 3,481−45.6%12.2% | 6,405+4.9%15.1% | 6,106−10.6%14.8% | 6,830+186%17.1% | 2,388+13.5%17.2% | 2,104—20.0% | 1,354+30.1%16.6% | 1,040—12.4% | |
| Current assets | 19,989+4.5%70.9% | 19,132−5.5%70.3% | 20,256−32.0%71.2% | 29,802−20.1%70.4% | 37,321−0.5%90.4% | 37,526+216%94.0% | 11,881+31.5%85.6% | 9,033—85.7% | 6,780−4.8%83.0% | 7,119—84.8% | |
| Property, plant and equipment | 4,471+4.2%15.9% | 4,291+11.8%15.8% | 3,838−1.3%13.5% | 3,887+251%9.2% | 1,106−5.2%2.7% | 1,168+90.8%2.9% | 612−28.8%4.4% | 859—8.1% | 932−6.5%11.4% | 997—11.9% | |
| Right-of-use (leased) assets | 2,956−0.3%10.5% | 2,966−15.6%10.9% | 3,514−7.2%12.3% | 3,787+3863%8.9% | 96−59.7%0.2% | 237−36.6%0.6% | 374—2.7% | — | — | — | |
| Other intangible assets | 685−6.2%2.4% | 730−3.2%2.7% | 754−4.2%2.7% | 787−2.7%1.9% | 809−4.1%2.0% | 844+4.5%2.1% | 807+27.7%5.8% | 632—6.0% | 427+72.4%5.2% | 248—3.0% | |
| Total assets | 28,200+3.6%100% | 27,219−4.4%100% | 28,461−32.8%100% | 42,332+2.5%100% | 41,293+3.4%100% | 39,919+188%100% | 13,882+31.6%100% | 10,545—100% | 8,170−2.7%100% | 8,394—100% | |
| Accounts payable | 2,267+37.4%8.0% | 1,650+69.2%6.1% | 975−59.2%3.4% | 2,392+94.8%5.7% | 1,228+96.4%3.0% | 625+9.1%1.6% | 573+26.3%4.1% | 453—4.3% | 772+151%9.5% | 308—3.7% | |
| Current liabilities | 8,194+13.8%29.1% | 7,202+61.7%26.5% | 4,454−36.0%15.7% | 6,959+45.2%16.4% | 4,792+30.7%11.6% | 3,666+52.4%9.2% | 2,406+51.9%17.3% | 1,584—15.0% | 1,389+25.4%17.0% | 1,108—13.2% | |
| Lease liabilities (non-current) | 2,879−4.0%10.2% | 3,000−10.1%11.0% | 3,336−8.7%11.7% | 3,653—8.6% | — | 96−59.7%0.2% | 237—1.7% | — | — | — | |
| Total liabilities | 11,152+7.2%39.5% | 10,405+28.3%38.2% | 8,107−26.3%28.5% | 11,006+130%26.0% | 4,792+27.4%11.6% | 3,762+42.2%9.4% | 2,646+67.0%19.1% | 1,584—15.0% | 1,494+17.1%18.3% | 1,276—15.2% | |
| Retained earnings | −32,017—−114% | −29,379—−108% | −23,312—−81.9% | −9,571—−22.6% | −910−125%−2.2% | 3,653−24.9%9.2% | 4,865+13.1%35.0% | 4,300—40.8% | 2,485−17.7%30.4% | 3,020—36.0% | |
| Shareholders' equity | 17,048+1.4%60.5% | 16,814−17.4%61.8% | 20,354−35.0%71.5% | 31,326−14.2%74.0% | 36,501+1.0%88.4% | 36,157+222%90.6% | 11,236+25.4%80.9% | 8,961—85.0% | 6,676−6.2%81.7% | 7,118—84.8% | |
| Total liabilities and equity | 28,200+3.6%100% | 27,219−4.4%100% | 28,461−32.8%100% | 42,332+2.5%100% | 41,293+3.4%100% | 39,919+188%100% | 13,882+31.6%100% | 10,545—100% | 8,170−2.7%100% | 8,394—100% | |
| Shares outstanding | 46+0.9%— | 46+0.6%— | 46r46+0.5%— | 45+1.8%— | 45+3.2%— | 43+9.5%— | 40+3.4%— | 38—— | 38−0.4%— | 38—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 811−8.8%2.0% | 888+2.1%2.6% | 870+48.2%3.1% | 587+26.8%2.1% | 463+10.6%2.0% | 419+23.0%1.7% | 340+10.0%1.5% | 309—1.8% | 301+10.7%2.4% | 272—2.2% | |
| Share-based compensation | 2,714+3.4%6.6% | 2,624−5.2%7.8% | 2,769−10.1%9.7% | 3,079+13.7%11.0% | 2,708+67.3%11.5% | 1,619+34.4%6.7% | 1,205+229%5.2% | 366—2.1% | 205+79.4%1.7% | 115—0.9% | |
| Cash from operating activities | 462—1.1% | −320—−1.0% | −4,893—−17.2% | −5,405—−19.4% | −4,320—−18.4% | −743−332%−3.1% | 321−78.3%1.4% | 1,480—8.5% | −332−117%−2.7% | 1,915—15.6% | |
| Capital expenditure | −933—−2.3% | −1,297—−3.9% | −783—−2.7% | −2,761—−9.9% | −346—−1.5% | −921—−3.8% | −201—−0.9% | −297—−1.7% | −203—−1.7% | −122—−1.0% | |
| Intangible assets bought | −24—−0.1% | −44—−0.1% | −32—−0.1% | −41—−0.1% | −29—−0.1% | −141—−0.6% | −224—−1.0% | −184—−1.1% | −212—−1.7% | −80—−0.7% | |
| Cash from investing activities | −950—−2.3% | −1,333—−4.0% | −815—−2.9% | −2,802—−10.0% | −366—−1.6% | −1,036−179%−4.3% | 1,310—5.7% | −1,730—−10.0% | −416—−3.4% | −190—−1.5% | |
| Shares issued | — | — | — | 407−67.8%1.5% | 1,261−95.3%5.4% | 26,728+5152%111% | 509+893%2.2% | 51—0.3% | — | — | |
| Shares bought back | — | — | — | — | — | — | −2.8—−0.0% | — | — | — | |
| Cash from financing activities | −221—−0.5% | −249—−0.7% | −219−178%−0.8% | 279−89.7%1.0% | 2,705−88.4%11.5% | 23,224+4533%96.1% | 501+3374%2.2% | 14—0.1% | −141—−1.1% | −81—−0.7% | |
| Change in cash | −709—−1.7% | −1,901—−5.7% | −5,926—−20.8% | −7,927—−28.4% | −1,980−109%−8.4% | 21,444+906%88.7% | 2,132—9.2% | −236—−1.4% | −889−154%−7.2% | 1,645—13.4% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 46,272+18.4%100% | 11,567+11.2%100% | 12,045+18.2%100% | 11,765+22.1%100% | 10,895*+23.3%100% | 10,402+27.2%100% | 10,195+20.9%100% | 9,635+17.5%100% | 8,839*+23.0%100% | 8,180—100% | 8,430—100% | 8,198—100% | 7,186*—100% | |
| Cost of revenue | 16,831+14.3%36.4% | 4,020−2.8%34.8% | 4,199+12.9%34.9% | 4,533+26.3%38.5% | 4,078*+24.5%37.4% | 4,138+38.2%39.8% | 3,719+26.1%36.5% | 3,589+16.0%37.2% | 3,276*+14.7%37.1% | 2,994—36.6% | 2,950—35.0% | 3,095—37.7% | 2,855*—39.7% | |
| Gross profit | 29,441+20.9%63.6% | 7,546+20.5%65.2% | 7,846+21.2%65.1% | 7,231+19.6%61.5% | 6,817*+22.6%62.6% | 6,265+20.8%60.2% | 6,476+18.2%63.5% | 6,046+18.5%62.8% | 5,563*+28.4%62.9% | 5,186—63.4% | 5,480—65.0% | 5,103—62.3% | 4,331*—60.3% | |
| Research and development | 4,812+10.4%10.4% | 1,281+37.3%11.1% | 1,069−10.5%8.9% | 1,317+18.1%11.2% | 1,145*+2.7%10.5% | 933−39.2%9.0% | 1,195+5.3%11.7% | 1,115−24.5%11.6% | 1,114*−13.5%12.6% | 1,534—18.8% | 1,134—13.5% | 1,476—18.0% | 1,288*—17.9% | |
| Selling, general and administrative | 24,431+5.5%52.8% | 5,868−2.1%50.7% | 5,940+10.3%49.3% | 6,582+10.5%55.9% | 6,041*+3.7%55.4% | 5,995+16.9%57.6% | 5,384+1.2%52.8% | 5,959+11.2%61.9% | 5,827*+16.2%65.9% | 5,128—62.7% | 5,320—63.1% | 5,358—65.4% | 5,013*—69.8% | |
| Operating expenses | 30,039+5.9%64.9% | 7,359+3.2%63.6% | 7,219+6.3%59.9% | 8,096+11.0%68.8% | 7,365*+3.0%67.6% | 7,132+3.5%68.6% | 6,788+1.7%66.6% | 7,291+3.2%75.7% | 7,152*+9.6%80.9% | 6,889—84.2% | 6,672—79.1% | 7,065—86.2% | 6,529*—90.9% | |
| Operating income | −598—−1.3% | 187—1.6% | 627—5.2% | −865—−7.4% | −547*—−5.0% | −868—−8.3% | −313—−3.1% | −1,245—−12.9% | −1,590*—−18.0% | −1,703—−20.8% | −1,192—−14.1% | −1,961—−23.9% | −2,198*—−30.6% | |
| Other non-operating income (expense) | −197−161%−0.4% | 49−45.3%0.4% | −369−399%−3.1% | 58−26.6%0.5% | 65*+108%0.6% | 90−26.9%0.9% | 123−39.4%1.2% | 79+210%0.8% | 31*−82.3%0.4% | 122—1.5% | 203—2.4% | 25—0.3% | 177*—2.5% | |
| Income before tax | −795—−1.7% | 236—2.0% | 258—2.1% | −807—−6.9% | −482*—−4.4% | −778—−7.5% | −190—−1.9% | −1,166—−12.1% | −1,558*—−17.6% | −1,581—−19.3% | −989—−11.7% | −1,936—−23.6% | −2,021*—−28.1% | |
| Income tax | — | 18—0.2% | 5.8−66.6%0.0% | — | 4.7*—0.0% | −0.2—−0.0% | 17—0.2% | — | — | — | — | — | 5,445*—75.8% | |
| Net income attributable to shareholders | −823—−1.8% | 218—1.9% | 252—2.1% | −807—−6.9% | −487*—−4.5% | −778—−7.5% | −207—−2.0% | −1,166—−12.1% | −1,561*—−17.7% | −1,581—−19.3% | −989—−11.7% | −1,936—−23.6% | −7,466*—−104% | |
| Earnings per share, basic | — | 0.00—— | 0.01—— | -0.02—— | — | -0.02—— | 0.00—— | -0.03r0.03−175%— | — | -0.03—— | -0.02—— | 0.04r-0.04—— | — | |
| Earnings per share, diluted | — | 0.00—— | 0.01—— | -0.02—— | — | -0.02r0.02−167%— | 0.00−100%— | -0.03r0.03−175%— | — | 0.03r-0.03—— | 0.02r-0.02—— | 0.04r-0.04—— | — | |
| Shares, weighted average (basic) | 46+0.0%— | 46+0.0%— | 46−0.2%— | 46+0.8%— | — | 46+0.8%— | 46+0.8%— | 46+0.6%— | — | 46—— | 46—— | 46—— | — | |
| Shares, weighted average (diluted) | 47+1.1%— | 47+1.1%— | 50+7.2%— | 46+0.8%— | — | 46+0.8%— | 46+0.8%— | 46+0.6%— | — | 46—— | 46—— | 46—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 7,364—25.6% | 7,364−13.0%25.6% | 8,288+2.9%29.6% | 8,768+0.4%30.7% | 8,872−7.4%31.5% | 8,464−3.9%31.2% | 8,055−23.0%31.6% | 8,736−19.3%32.1% | 9,581−16.6%35.2% | 8,806—32.2% | 10,458—38.3% | 10,820—39.3% | 11,482—40.3% | |
| Receivables | 6,382—22.2% | 6,382+17.9%22.2% | 5,028+2.0%18.0% | 5,983+0.6%20.9% | 6,210+8.6%22.0% | 5,412+4.8%20.0% | 4,929−15.7%19.3% | 5,949+35.4%21.9% | 5,721+41.4%21.0% | 5,165—18.9% | 5,846—21.4% | 4,393—16.0% | 4,045—14.2% | |
| Inventory | 4,692—16.3% | 4,692+6.4%16.3% | 4,511+14.3%16.1% | 4,476+36.5%15.7% | 3,678+31.2%13.0% | 4,412+12.3%16.3% | 3,948+52.5%15.5% | 3,279+4.2%12.0% | 2,804−19.5%10.3% | 3,928—14.3% | 2,589—9.5% | 3,147—11.4% | 3,481—12.2% | |
| Current assets | 20,137—70.0% | 20,137+3.7%70.0% | 19,514+11.0%69.8% | 20,588+8.4%72.0% | 19,989+4.5%70.9% | 19,419+2.6%71.6% | 17,579−9.2%68.9% | 18,999−2.5%69.8% | 19,132−5.5%70.3% | 18,929—69.1% | 19,366—70.9% | 19,479—70.8% | 20,256—71.2% | |
| Property, plant and equipment | 4,004—13.9% | 4,004−5.5%13.9% | 3,930−10.1%14.1% | 4,336−4.4%15.2% | 4,471+4.2%15.9% | 4,236−6.9%15.6% | 4,371+18.8%17.1% | 4,534+20.7%16.7% | 4,291+11.8%15.8% | 4,552—16.6% | 3,679—13.5% | 3,756—13.7% | 3,838—13.5% | |
| Right-of-use (leased) assets | 2,653—9.2% | 2,653−0.5%9.2% | 2,756−0.5%9.9% | 2,857−0.4%10.0% | 2,956−0.3%10.5% | 2,668−12.9%9.8% | 2,768−18.9%10.8% | 2,868−16.4%10.5% | 2,966−15.6%10.9% | 3,064—11.2% | 3,415—12.5% | 3,429—12.5% | 3,514—12.3% | |
| Other intangible assets | 1,684—5.8% | 1,684+147%5.8% | 1,663+138%5.9% | 711−0.7%2.5% | 685−6.2%2.4% | 682−8.7%2.5% | 699−6.2%2.7% | 716−2.9%2.6% | 730−3.2%2.7% | 746—2.7% | 745—2.7% | 738—2.7% | 754—2.7% | |
| Total assets | 28,784—100% | 28,784+6.2%100% | 27,962+9.6%100% | 28,592+5.1%100% | 28,200+3.6%100% | 27,104−1.0%100% | 25,516−6.5%100% | 27,216−1.0%100% | 27,219−4.4%100% | 27,390—100% | 27,304—100% | 27,501—100% | 28,461—100% | |
| Accounts payable | 1,875—6.5% | 1,875+0.2%6.5% | 2,913+166%10.4% | 2,636+30.9%9.2% | 2,267+37.4%8.0% | 1,872+12.1%6.9% | 1,095−31.4%4.3% | 2,014+13.5%7.4% | 1,650+69.2%6.1% | 1,670—6.1% | 1,596—5.8% | 1,774—6.5% | 975—3.4% | |
| Current liabilities | 6,792—23.6% | 6,792−13.3%23.6% | 7,180+18.7%25.7% | 8,852+13.5%31.0% | 8,194+13.8%29.1% | 7,834+23.9%28.9% | 6,051+17.8%23.7% | 7,799+60.7%28.7% | 7,202+61.7%26.5% | 6,324—23.1% | 5,137—18.8% | 4,853—17.6% | 4,454—15.7% | |
| Lease liabilities (non-current) | 2,546—8.8% | 2,546−5.3%8.8% | 2,659−4.8%9.5% | 2,771−4.4%9.7% | 2,879−4.0%10.2% | 2,688−13.3%9.9% | 2,794−12.8%10.9% | 2,898−10.6%10.6% | 3,000−10.1%11.0% | 3,102—11.3% | 3,203—11.7% | 3,242—11.8% | 3,336—11.7% | |
| Total liabilities | 9,389—32.6% | 9,389−11.7%32.6% | 9,910+10.2%35.4% | 11,669+7.3%40.8% | 11,152+7.2%39.5% | 10,639+10.2%39.3% | 8,990+4.5%35.2% | 10,871+29.7%39.9% | 10,405+28.3%38.2% | 9,657—35.3% | 8,599—31.5% | 8,383—30.5% | 8,107—28.5% | |
| Retained earnings | −32,353—−112% | −32,353—−112% | −32,571—−116% | −32,824—−115% | −32,017—−114% | −31,530—−116% | −30,752—−121% | −30,545—−112% | −29,379—−108% | −27,818—−102% | −26,237—−96.1% | −25,248—−91.8% | −23,312—−81.9% | |
| Shareholders' equity | 19,395—67.4% | 19,395+17.8%67.4% | 18,052+9.2%64.6% | 16,922+3.5%59.2% | 17,048+1.4%60.5% | 16,465−7.2%60.7% | 16,526−11.6%64.8% | 16,345−14.5%60.1% | 16,814−17.4%61.8% | 17,733—64.7% | 18,705—68.5% | 19,118—69.5% | 20,354—71.5% | |
| Total liabilities and equity | 28,784—100% | 28,784+6.2%100% | 27,962+9.6%100% | 28,592+5.1%100% | 28,200+3.6%100% | 27,104−1.0%100% | 25,516−6.5%100% | 27,216−1.0%100% | 27,219−4.4%100% | 27,390—100% | 27,304—100% | 27,501—100% | 28,461—100% | |
| Shares outstanding | 46—— | 46+0.2%— | 46−0.2%— | 46−0.0%— | 46+0.9%— | 46+1.0%— | 46+0.9%— | 46+0.9%— | 46+0.6%— | 46—— | 46—— | 46—— | 46r46—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 797−5.5%1.7% | 210+2.7%1.8% | 210+0.3%1.7% | 198−9.1%1.7% | 179*−15.3%1.6% | 204−10.2%2.0% | 209−3.8%2.1% | 217−6.1%2.3% | 211*−7.4%2.4% | 228—2.8% | 218—2.6% | 231—2.8% | 228*—3.2% | |
| Share-based compensation | 3,040+24.6%6.6% | 928*+47.9%8.0% | 458*+10.1%3.8% | 682−2.3%5.8% | 973*+39.0%8.9% | 627*+2.9%6.0% | 416*−32.4%4.1% | 698−0.3%7.2% | 700*+79.8%7.9% | 610*—7.5% | 615*—7.3% | 700—8.5% | 389*—5.4% | |
| Cash from operating activities | 443+44.1%1.0% | −883*−1449%−7.6% | 216*—1.8% | 15—0.1% | 1,095*+16.5%10.0% | 65*—0.6% | −460*−4161%−4.5% | −237—−2.5% | 940*−14.3%10.6% | −924*—−11.3% | 11*—0.1% | −347—−4.2% | 1,097*—15.3% | |
| Capital expenditure | −830—−1.8% | −268*—−2.3% | −108*—−0.9% | −46—−0.4% | −408*—−3.7% | −52*—−0.5% | −29*—−0.3% | −443—−4.6% | — | −1,084*—−13.2% | −124*—−1.5% | −133—−1.6% | −196*—−2.7% | |
| Intangible assets bought | −592—−1.3% | −111*—−1.0% | −417*—−3.5% | −44—−0.4% | −21*—−0.2% | 0*—0.0% | 0*—0.0% | −3.4—−0.0% | −1.3*—−0.0% | −19*—−0.2% | −24*—−0.3% | 0—0.0% | −12*—−0.2% | |
| Cash from investing activities | −1,623—−3.5% | −534*—−4.6% | −577*—−4.8% | −90—−0.8% | −422*−931%−3.9% | −52*—−0.5% | −29*—−0.3% | −447—−4.6% | 51*—0.6% | −1,102*—−13.5% | −149*—−1.8% | −133—−1.6% | −208*—−2.9% | |
| Cash from financing activities | 80—0.2% | 493*+24.4%4.3% | −119*—−1.0% | −29—−0.2% | −265*—−2.4% | 396*+5.8%3.8% | −192*—−1.9% | −161—−1.7% | −216*—−2.4% | 374*—4.6% | −225*—−2.7% | −182—−2.2% | −178*—−2.5% | |
| Change in cash | −1,100—−2.4% | −924*−326%−8.0% | −480*—−4.0% | −104—−0.9% | 408*−47.3%3.7% | 409*—3.9% | −681*—−6.7% | −845—−8.8% | 775*+9.1%8.8% | −1,652*—−20.2% | −362*—−4.3% | −662—−8.1% | 710*—9.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Repro Med Systems sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- 🇺🇸 USA$30 M74%+9.9%
- Non-US(total)$11 M26%+77%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Repro Med Systems#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Linda Tharby | $1.7 M | $3.2 M | $1.8 M | $163 |
| 2024Linda Tharby | $1.3 M | $1.9 M | $599 K | $108 |
| 2023Linda Tharby | $713 K | −$1.2 M | $547 K | $69 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Repro Med Systems#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 4 · Material agreement 5 · New debt 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Auditor changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Lobbying by Repro Med Systems#
$0 spent on lobbying the US Congress and federal agencies in 2018.
Lobbying firms hired in 2018
Dan Burton International LLC
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2018 | $0 | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Repro-Med Systems, Inc., d/b/a RMS Medical Products”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Product recalls by Repro Med Systems#
2 recalls since 2015, 1,990 units in the notices that give a number. Medical devices (FDA): 2.
| Date | What and why | Units | Notice |
|---|---|---|---|
| 20" 2-Needle 26-Gauge 6mm HlgH-Flo Subcutaneous Safety Needle Sets" Product # RMS22606 - Product Usage: RMS HlgH-Flo Subcutaneous Safety Needle Sets are intended for the delivery of medication to the subcutaneous tissue.Mislabeled needle lengthsMedical devicesClass II | 1,990 | Z-0051-2020 | |
| Freedom60 Precision Flow Rate Tubing Sets, REF/Part Numbers F900, F2400, F60, F10, F275, F600, F45, F1200 F180. (and 1 more products)On 2/24/2016 during post sterilization inspection of part number F180 Precision Flow Rate Tubing, Lot number 1.042/16 the firm found 701 out of 3,195 were rejected due to visual defect, gap in the supplier s manufacturing seal for Part number #317036 5 X 6.5 ST Bag Combo. the firm decided to recall Precision Flow Rate Tubing and RMS HIgH-Flo Subcutaneous Safety Needles Sets due to the sterile barrier packaging being found to have gaps during post-sterilization inspection of one lot of flow tubing, in which 701 out of 3,195 units were rejected for not passing inspection. The firm determined that the issue was large than just the one lot and recalled the product via March 10, 2016 Voluntary Medical Device Corrections and Removal Notification to customers. The recall was conducted without FDA notification.Medical devicesClass II | — | Z-0317-2018 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Repro Med Systems compares in Medical Instruments
- Market cap$140 M · higher than 20% of 116
- Revenue$41 M · higher than 14% of 120
- Net margin-1.8% · higher than 21% of 114
- Revenue growth22.2% · higher than 88% of 49
- Price / sales3.0× · lower than 51% of 85
- Price / book8.2× · lower than 12% of 84
- FCF yield-0.3% · higher than 34% of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Repro Med Systems🇺🇸 | $140 M | — | -1.8% | +22.2% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Repro Med Systems? Verify and update this profile — free
Show Repro Med Systems's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.